Arnaud Augert
Assistant ProfessorCards
Appointments
Additional Titles
Assistant Professor, Pathology
Full Member, Genomics
Contact Info
Appointments
Additional Titles
Assistant Professor, Pathology
Full Member, Genomics
Contact Info
Appointments
Additional Titles
Assistant Professor, Pathology
Full Member, Genomics
Contact Info
About
Copy Link
Titles
Assistant Professor
Assistant Professor, Pathology; Full Member, Genomics
Biography
Dr. Arnaud A. Augert hails from Institut Pasteur / Institut de Biologie de Lille in France, where he trained as a molecular and cellular biologist. His PhD work focused on the study of Cellular Senescence, a process intimately connected to a series of age-related conditions, including cancer. In his subsequent postdoctoral research at the Fred Hutchinson Cancer Center in Seattle, Dr. Augert devoted his efforts to the study of small cell lung cancer (SCLC), an aggressive and devastating neuroendocrine tumor.
Notable highlights among his discoveries include the characterization of transcriptional and epigenetic mechanisms underlying SCLC initiation and progression, and the identification of novel therapeutic strategies for this tumor type. Most strikingly, Dr. Augert and his colleagues uncovered the tumor suppressive networks of SCLC and a “tumor suppressive branch” of the MYC network. His work has been published in scientific journals such as Cancer Cell, Cancer Discovery, Journal of Thoracic Oncology, Science Signaling and EMBO. He is an avid collaborator and a co-author on numerous studies published in journals such as Cell, Nature Communication and Genes & Development. Dr. Augert was awarded several PhD fellowships, a UALC/LCRF grant, the ATIP-AVENIR program and the Yale Cancer Center (YCC) K12 Calabresi Immuno-Oncology Training Program.
Mentorship is an area of great significance to Dr. Augert, mentoring trainees is a great source of pride. He has trained, supervised, and managed undergraduates, lab aids, research technicians and graduate students, many of whom have moved onto graduate programs, medical school, and roles with greater responsibility. As a newly appointed Assistant Professor in the Department of Pathology, Dr. Augert will focus his efforts on building a multidisciplinary research program that combines cell biology, human and mouse genetics and cutting-edge molecular biology to study SCLC biology and identify novel therapeutic approaches for this truly lethal form of lung cancer.
Appointments
Pathology
Assistant ProfessorPrimary
Other Departments & Organizations
Education & Training
- PhD
- Pasteur Institute/USTL, Molecular & Cellular Biology
- MPhil
- USTL, Cellular Biology & Physiology
- BS
- University of Valencia, Cellular Biology & Physiology
Research
Copy Link
Research at a Glance
Publications Timeline
Publications
2021
Protein neddylation as a therapeutic target in pulmonary and extrapulmonary small cell carcinomas
Norton J, Augert A, Eastwood E, Basom R, Rudin C, MacPherson D. Protein neddylation as a therapeutic target in pulmonary and extrapulmonary small cell carcinomas. Genes & Development 2021, 35: 870-887. PMID: 34016692, PMCID: PMC8168556, DOI: 10.1101/gad.348316.121.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAnimalsBasic Helix-Loop-Helix Transcription FactorsCarcinoma, Small CellCell DeathCell Line, TumorCOP9 Signalosome ComplexCyclopentanesDisease Models, AnimalGene Expression Regulation, NeoplasticHeterograftsHumansLung NeoplasmsMiceNEDD8 ProteinNeuroendocrine CellsProteinsPyrimidinesRepressor ProteinsSequence DeletionConceptsSmall cell lung carcinomaSmall cell carcinomaExtrapulmonary small cell carcinomaNeddylation inhibitionCell carcinomaCell statesGenome-scale CRISPR/Therapeutic targetPatient-derived xenograft modelsCell linesDeletion of componentsSolid tumor malignanciesCell lung carcinomaNovel therapeutic approachesPotential therapeutic targetSuppressor screenSCLC cell linesCOP9 signalosomeProtein neddylationCRISPR/Genetic suppressionPathway genesPDX modelsMajor regulatorLung carcinoma
2020
MAX Functions as a Tumor Suppressor and Rewires Metabolism in Small Cell Lung Cancer.
Augert A, Mathsyaraja H, Ibrahim AH, Freie B, Geuenich MJ, Cheng PF, Alibeckoff SP, Wu N, Hiatt JB, Basom R, Gazdar A, Sullivan LB, Eisenman RN, MacPherson D. MAX Functions as a Tumor Suppressor and Rewires Metabolism in Small Cell Lung Cancer. Cancer Cell 2020, 38: 97-114.e7. PMID: 32470392, DOI: 10.1016/j.ccell.2020.04.016.Peer-Reviewed Original Research
2019
Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition
Augert A, Eastwood E, Ibrahim A, Wu N, Grunblatt E, Basom R, Liggitt D, Eaton K, Martins R, Poirier J, Rudin C, Milletti F, Cheng W, Mack F, MacPherson D. Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition. Science Signaling 2019, 12 PMID: 30723171, PMCID: PMC6530478, DOI: 10.1126/scisignal.aau2922.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAnimalsBasic Helix-Loop-Helix Transcription FactorsCell Line, TumorEnzyme InhibitorsGene Expression Regulation, NeoplasticHistone DemethylasesHumansKaplan-Meier EstimateLung NeoplasmsMice, Inbred NODMice, KnockoutMice, SCIDReceptors, NotchSignal TransductionSmall Cell Lung CarcinomaTumor BurdenXenograft Model Antitumor AssaysConceptsSmall cell lung cancerCell lung cancerNonsmall cell lung cancerLung cancerNotch activationLSD1 inhibitionPatient-derived xenograft modelsLSD1 inhibitorsReactivation of NotchFirst-line standardExpression of Ascl1Durable tumor regressionTranscription factor Ascl1Notch pathway activationLineage genesKnockdown studiesNotch pathwayDownstream signalingCare treatmentPDX modelsTumor regressionTargeted therapySCLC tumorigenesisActionable mutationsXenograft model
2018
Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition.
Jia D, Augert A, Kim DW, Eastwood E, Wu N, Ibrahim AH, Kim KB, Dunn CT, Pillai SPS, Gazdar AF, Bolouri H, Park KS, MacPherson D. Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition. Cancer Discov 2018, 8: 1422-1437. PMID: 30181244, DOI: 10.1158/2159-8290.CD-18-0385.Peer-Reviewed Original Research
2017
Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance).
Augert A, Zhang Q, Bates B, Cui M, Wang X, Wildey G, Dowlati A, MacPherson D. Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance). J Thorac Oncol 2017, 12: 704-713. PMID: 28007623, DOI: 10.1016/j.jtho.2016.12.011.Peer-Reviewed Original Research
2016
The PLA2R1-JAK2 pathway upregulates ERRα and its mitochondrial program to exert tumor-suppressive action.
Griveau A, Devailly G, Eberst L, Navaratnam N, Le Calvé B, Ferrand M, Faull P, Augert A, Dante R, Vanacker JM, Vindrieux D, Bernard D. The PLA2R1-JAK2 pathway upregulates ERRα and its mitochondrial program to exert tumor-suppressive action. Oncogene 2016, 35: 5033-42. PMID: 27041564, DOI: 10.1038/onc.2016.43.Peer-Reviewed Original ResearchMultidrug resistance protein 3 loss promotes tumor formation by inducing senescence escape.
Wiel C, Gras B, Vindrieux D, Warnier M, Gitenay D, Le Calvé B, Ferrand M, Augert A, Bernard D. Multidrug resistance protein 3 loss promotes tumor formation by inducing senescence escape. Oncogene 2016, 35: 1596-601. PMID: 26073088, DOI: 10.1038/onc.2015.218.Peer-Reviewed Original Research
2014
Treating transcriptional addiction in small cell lung cancer.
Augert A, MacPherson D. Treating transcriptional addiction in small cell lung cancer. Cancer Cell 2014, 26: 783-784. PMID: 25490443, DOI: 10.1016/j.ccell.2014.11.012.Peer-Reviewed Original ResearchEndoplasmic reticulum calcium release through ITPR2 channels leads to mitochondrial calcium accumulation and senescence.
Wiel C, Lallet-Daher H, Gitenay D, Gras B, Le Calvé B, Augert A, Ferrand M, Prevarskaya N, Simonnet H, Vindrieux D, Bernard D. Endoplasmic reticulum calcium release through ITPR2 channels leads to mitochondrial calcium accumulation and senescence. Nat Commun 2014, 5: 3792. PMID: 24797322, DOI: 10.1038/ncomms4792.Peer-Reviewed Original ResearchPTEN is a potent suppressor of small cell lung cancer.
Cui M, Augert A, Rongione M, Conkrite K, Parazzoli S, Nikitin AY, Ingolia N, MacPherson D. PTEN is a potent suppressor of small cell lung cancer. Mol Cancer Res 2014, 12: 654-9. PMID: 24482365, DOI: 10.1158/1541-7786.MCR-13-0554.Peer-Reviewed Original Research
Get In Touch
Copy Link
Contacts
Administrative Support
Locations
Lauder Hall
Academic Office
310 Cedar Street, Rm LH-315A
New Haven, CT 06510